NCT05123586

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	LY3361237	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2022-03-07
• Primary completion: 2023-12-29
• Completion: 2023-12-29
• First posted: 2021-11-17
• Last updated: 2025-01-20
• Results posted: 2025-01-20

Locations

50 sites across 8 countries: United States, Argentina, Czechia, France, Mexico, Poland, Puerto Rico, Taiwan

Regulatory

• FDA-regulated drug study